Aju Business Daily

SEOUL -- Standigm, a startup known for AI-based material optimization platforms, joined hands with SK C&C, the information technology wing of South Korean conglomerate SK Group, to unveil an artificial intelligence service that enables the quick traction of genes and proteins for the development of new drugs. It can be used free of charge by companies and researchers.

The two companies will test-run iCLUE & ASK, a target discovery service. When searching for diseases under research, AI algorithms recommend candidates for "targets," which are the cause of disease. SK C&C said in a statement that a large amount of knowledge is visualized and presented in the form of a network graph along with recommended evidence information.

The service can reduce time and money in the process of searching and analyzing disease and drug information. Standigm removes the traditional guesswork from data analysis by using AI, automatically examining whole biomedical databases to learn what is hiding just out of sight. In December 2019, the startup partnered with CJ HealthCare, a bio company, to develop innovative anti-cancer drug candidates.